葵花药业，迎上市以来首亏！

Core Viewpoint - The company, Kew Flower Pharmaceutical, is experiencing its most severe financial challenge since its listing, with a projected net loss for 2025 of up to 380 million yuan, a significant decline from a peak profit of over 1.1 billion yuan in 2023 [1][3]. Financial Performance - The forecasted net profit attributable to shareholders for 2025 is expected to be between -380 million yuan and -240 million yuan, a year-on-year decrease of 177.23% to 148.78% from 492 million yuan in the previous year [1][3]. - The projected net profit after deducting non-recurring gains and losses is estimated to be between -420 million yuan and -285 million yuan, down 182.68% from 345 million yuan in the same period last year [1][4]. Historical Performance - Kew Flower Pharmaceutical's net profit has consistently increased from 2014 to 2023, with a notable growth of over 20% for three consecutive years from 2021 to 2023. However, in 2024, the profit dropped by 56.03% to only 492 million yuan [5][6]. Reasons for Performance Decline - The company has undertaken channel and terminal adjustments in response to industry trends, leading to a decrease in sales revenue. This strategic move aims to optimize channels and control inventory levels, which has negatively impacted current sales but is intended to support future sustainable growth [4][5]. - A reduction in production and sales volume has led to increased fixed cost allocation and a decline in gross profit margin due to fluctuating prices in the upstream herbal medicine market [4][5]. - The company has increased its marketing and branding efforts, resulting in higher sales expenses, as it seeks to navigate the challenges posed by the traditional pharmaceutical industry's adjustments [4][5]. - Despite the current financial pressures, the company continues to invest in research and development, focusing on specific advantageous areas to enhance its product pipeline [5].